244 related articles for article (PubMed ID: 30462853)
21. Recent research advances in ATX inhibitors: An overview of primary literature.
Zhang C; Liu Y; Zhou Q; Fan H; Liu X; Hu J
Bioorg Med Chem; 2023 Jul; 90():117374. PubMed ID: 37354726
[TBL] [Abstract][Full Text] [Related]
22. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
23. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
[TBL] [Abstract][Full Text] [Related]
24. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
25. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
[TBL] [Abstract][Full Text] [Related]
26. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
27. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
28. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
29. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
30. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
31. Autotaxin in liver fibrosis.
Ikeda H; Yatomi Y
Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
[TBL] [Abstract][Full Text] [Related]
32. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.
Banerjee S; Lee S; Norman DD; Tigyi GJ
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080255
[TBL] [Abstract][Full Text] [Related]
33. Design and Development of Autotaxin Inhibitors.
Jia Y; Li Y; Xu XD; Tian Y; Shang H
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
[TBL] [Abstract][Full Text] [Related]
34. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity.
Kang TS; Wang W; Zhong HJ; Liang JX; Ko CN; Lu JJ; Chen XP; Ma DL; Leung CH
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):256-263. PubMed ID: 27888146
[TBL] [Abstract][Full Text] [Related]
35. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.
Herr DR; Chew WS; Satish RL; Ong WY
Mol Neurobiol; 2020 Jan; 57(1):372-392. PubMed ID: 31364025
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
37. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
40. Autotaxin-Lysophosphatidic Acid Pathway in Intraocular Pressure Regulation and Glaucoma Subtypes.
Honjo M; Igarashi N; Kurano M; Yatomi Y; Igarashi K; Kano K; Aoki J; Weinreb RN; Aihara M
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):693-701. PubMed ID: 29392315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]